Sunday, April 27, 2025 9:52:31 AM
Galzus Research,
Why are you being defensive about the 73 authors? You claim that DCVax-L will be approved so maybe those 73 agree with the data interpretation as presented by Dr Linda Liau, Dr Roger Stupp and NWBO. Observations that a stronger trial design should be possible for future trials does not take away from the extensive checks and balances put together for interpretation of data for this one which peer reviewers agreed were “adequate”. Those who have not reviewed the data and methods as well as these 73 are really in no position to make judgments about the methods and conclusions agreed upon by them. Questions are fine, just as those 73 might have had, but conclusions are another matter because those conclusions themselves must be checked for bias the same way the data was checked down on multiple ways for bias. I’m sure you can understand what I am saying; ). Best wishes.
Why are you being defensive about the 73 authors? You claim that DCVax-L will be approved so maybe those 73 agree with the data interpretation as presented by Dr Linda Liau, Dr Roger Stupp and NWBO. Observations that a stronger trial design should be possible for future trials does not take away from the extensive checks and balances put together for interpretation of data for this one which peer reviewers agreed were “adequate”. Those who have not reviewed the data and methods as well as these 73 are really in no position to make judgments about the methods and conclusions agreed upon by them. Questions are fine, just as those 73 might have had, but conclusions are another matter because those conclusions themselves must be checked for bias the same way the data was checked down on multiple ways for bias. I’m sure you can understand what I am saying; ). Best wishes.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
